CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing new epilepsy treatments by targeting the purinergic system, specifically the P2X7 receptor and Adenosine kinase. By using advanced animal models and human cells, it aims to demonstrate the combined therapeutic potential of these targets to improve seizure control and modify disease pro…
Current epilepsy therapies, based on mediating excitation or inhibition, are ineffective in 30% of patients & have no impact on disease progression, demonstrating an urgent need for new therapies.
Mounting evidence showed the therapeutic potential of targeting the purinergic system during epilepsy with the disease-modifying effects observed via targeting the P2X7 receptor & Adenosine kinase (ADK) being a promise. P2X7 & ADK are increased in the brain in experimental models of epilepsy and in pat…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United States, New Brunswick
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
